FDA Approves Nivolumab and Ipilimumab for Treatment of Renal Cell Carcinoma

On April 16, 2018, the Food and Drug Administration granted approval to nivolumab and ipilimumab (Opdivo and Yervoy, Bristol-Myers Squibb Co.) in combination for the treatment of intermediate or poor risk previously untreated advanced renal cell carcinoma.

Read the full press release here.

Posted 4/16/2018